公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companionanimal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
公司地址 10 Sylvan Way, Parsippany, NJ, USA, 07054
電話號碼 +1 973 822-7000
傳真號碼 --
公司網頁 https://www.zoetis.com
員工數量 14500
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Wetteny Joseph Executive Vice President, Principal Accounting Officer and Chief Financial Officer 美元 800.00K 12/02/2026
Mr. Nick Ashton Executive Vice President and President, Global Manufacturing and Supply -- 12/02/2026
Ms. Kristin C. Peck Director and Chief Executive Officer 美元 1.35M 08/04/2026
Ms. Roxanne Lagano Executive Vice President, General Counsel and Corporate Secretary 美元 700.00K 12/02/2026
Mr. Jamie Brannan Executive Vice President and Chief Commercial Officer 美元 720.00K 12/02/2026
Dr. Kevin Esch Executive Vice President and President, Research and Development -- 12/02/2026
Mr. Keith Sarbaugh Executive Vice President, Chief Digital Officer and Chief Technology Officer -- 12/02/2026
Ms. Julie Fuller Executive Vice President, Global Operations and Chief Human Resources Officer -- 12/02/2026
Ms. Rimma Driscoll Executive Vice President and Head of Global Strategy, Commercial and Business Development and Global BioDevices -- 12/02/2026
Ms. Jeannette Ferran Astorga Executive Vice President, Corporate Affairs and Chief Sustainability Officer -- 12/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Gregory Norden Independent Director 08/04/2026
Ms. Louise M. Parent Independent Director 08/04/2026
Mr. Michael B. McCallister Chairman of the Board 08/04/2026
Mr. Paul M. Bisaro Independent Director 08/04/2026
Mr. Gavin D.K. Hattersley Independent Director 08/04/2026
Ms. Vanessa Broadhurst Independent Director 08/04/2026
Mr. Frank A. D’Amelio Independent Director 08/04/2026
Mr. Sanjay Khosla Independent Director 08/04/2026
Ms. Kristin C. Peck Director and Chief Executive Officer 08/04/2026
Dr. Willie M. Reed, PhD Independent Director 08/04/2026
Mr. Mark Stetter Independent Director 08/04/2026
Ms. Antoinette R. Leatherberry Independent Director 08/04/2026
Ms. Stephanie Tilenius Director 08/04/2026
 
所屬ETF (更新日期: 02/05/2026 04:02)
代號 名稱 佔比% 持有日期
JUDOJanus Henderson U.S. Eq Enhanced Inc ETF0.0001%29/04/2026
EMOTFirst Trust S&P 500 Economic Moat ETF0.0001%29/04/2026
HQGOHartford US Quality Growth ETF0.0001%29/04/2026
XRMIGlobal X S&P 500® Risk Managed Inc ETF0.0001%29/04/2026
PHDGInvesco S&P 500® Downside Hedged ETF0.0001%29/04/2026
CDEICalvert US Large-Cp Div, Eq AndIncETF0.0001%29/04/2026
SAWGAAM Sawgrass U.S. Lg Cp Qual Gr ETF0.0001%29/04/2026
EBILongview Advantage ETF0.0001%29/04/2026
RAUSRACWI US ETF0.0001%29/04/2026
AVTMAvantis Total Equity Markets ETF0.0001%29/04/2026
SQSSapient Quality Select ETF0.0001%17/04/2026
ACGRAmerican Century Large Cap Growth ETF0.0001%31/03/2026
AVIEAvantis Inflation Focused Equity ETF0.0001%29/04/2026
ESMViShares ESG Optd MSCI USA Min Vol FacETF0.0001%29/04/2026
KNOWFundamentals First ETF0.0001%29/04/2026
MVALVanEck Morningstar Wide Moat Value ETF0.0001%29/04/2026
JUSAJPMorgan U.S. Research Enh Lg Cp ETF0.0001%29/04/2026
TOPCiShares S&P 500 3% Capped ETF0.0001%29/04/2026
SPYHNEOS S&P 500 Hedged Equity Income ETF0.00005%29/04/2026
BRESBurney U.S. Equity Select ETF0.00004%29/04/2026
  1    2    3    4    5    6    7    8    9    10    11    12    13   14    15    16    17    18    19    20  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.